MITOPRES: Mitochondrial Genetics of Presbycusis

Sponsor
University Hospital, Angers (Other)
Overall Status
Recruiting
CT.gov ID
NCT03720964
Collaborator
(none)
200
1
55
3.6

Study Details

Study Description

Brief Summary

The main goal of this study is to identify mitochondrial mutations associated with presbycusis. Patients affected by severe presbycusis and normal hearing controls (according to ISO7029 norm) will be enrolled if satisfying inclusion criteria (aged from 40 to 80 years old) in existing biocollections in the University Hospital of Angers. After DNA extraction, the mitochondrial genome will be sequenced and data in silico analysed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study will be proposed to patients consulting in the ENT department of the University Hospital of Angers. After clinical examination and audiometry recording, the eligibility criteria will be checked and inclusion in biocollections proposed. Presbycusis affected subjects will be enrolled in "Mitochondrial Disease biocollection" and normal hearing controls in "Healthy Volunteer biocollection". These biocollections have been approved by the board comitee "Centre de Protection des Personnes".

    After DNA extraction and mitochondrial sequencing, candidate variants will be selected by in silico analysis. The presence of mitochondrial variants in both groups (presbycusis and control) will be compared in multivariate analysis if needed.

    The nuclear DNA may be sequenced in order to complete the previous analysis and look for any candidate variant .

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Mitochondrial Genetics of Presbycusis
    Anticipated Study Start Date :
    Apr 1, 2019
    Anticipated Primary Completion Date :
    Nov 1, 2022
    Anticipated Study Completion Date :
    Nov 1, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    presbycusis affected patients

    affected by a more severe age related hearing loss than expected according to the norm ISO 7029

    controls

    not affected by age related hearing loss according to the norm ISO 7029

    Outcome Measures

    Primary Outcome Measures

    1. identification of mitochondrial mutations associated with presbycusis [the analysis will be conducted at the end of the inclusion of the 200 patients]

      Enrichment analysis will be perfomed with CHI2 test after Benjamini correction.

    Secondary Outcome Measures

    1. identification of genomic variants associated with presbycusis [the analysis will be conducted at the end of the inclusion of the 200 patients]

      enrichment of genomic variants will be analysed

    2. identification of DNA variants associated with environmental susceptibility [the analysis will be conducted at the end of the inclusion of the 200 patients]

      subgroup analysis will be performed in accordance with environmental exposition

    Other Outcome Measures

    1. identification of clinical features predicting some presbycusis forms [the analysis will be conducted at the end of the inclusion of the 200 patients]

      analysis of audiometric data after genetic analysis will be performed

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • age related hearing loss more severe than the predicted hearing thresholds according to the norm ISO7029, for the presbycusis population;

    • normal hearing according to norm ISO7029 for the control population

    Exclusion Criteria:
    • deafness diagnosed before 40 years old

    • exclusion criteria of one of the biocollection

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UH Angers Angers France 49933

    Sponsors and Collaborators

    • University Hospital, Angers

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Angers
    ClinicalTrials.gov Identifier:
    NCT03720964
    Other Study ID Numbers:
    • 49RC18_0148
    First Posted:
    Oct 26, 2018
    Last Update Posted:
    Apr 11, 2019
    Last Verified:
    Apr 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 11, 2019